CNBC December 5, 2023
Key Points
– Reproductive technology startup Orchid is launching the first commercially available whole genome sequencing test for embryos.
– The test can identify a child’s birth defects, neurodevelopmental disorders, chromosomal abnormalities and pediatric and adult-onset cancers before a pregnancy begins, Orchid said.
– It said the technology is for couples undergoing IVF, which is a type of treatment for people who are experiencing infertility or are at risk of passing on genetic problems.
Reproductive technology startup Orchid on Tuesday announced a comprehensive new genetic test that may help many prospective parents across the U.S. breathe a little easier.
The company is launching the first commercially available whole genome sequencing report for embryos, designed for couples undergoing in vitro...
Today's Sponsors
Today's Sponsor